Australia's Clarity Pharmaceuticals rises on deal with SpectronRx
17/06/2025 04:38
** Shares of Clarity Pharmaceuticals CU6.AX rises as much as 6.3% to A$2.37, up for second straight session ** Stock among the top percentage gainers on the benchmark index .AXJO ** Co enters a commercial manufacturing agreement for its diagnostic product, Cu-64 SAR-bisPSMA, with radiopharmaceutical developer SpectronRx ** SpectronRx' Indiana facility to provide commercial-scale manufacturing of the product and will enable distribution to all 50 U.S. states - co ** Stock is down 43.8%, YTD (Reporting by Anjali Singh in Bengaluru) ((anjali.singh2@thomsonreuters.com))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial